Orion Oyj: the Finnish pharma nobody talks about
2026-07-07 · By Lubin Danilo, founder of Lubin Investment
ORNBV.HE: see the full analysis on Lubin Investment
Orion Oyj, a Finnish pharmaceutical company specialized in central nervous system treatments and veterinary medicine, passes 9 of the 10 criteria in my screener. Its quality is real, but the stock trades at roughly 45 times its free cash flow, a price that leaves little room for disappointment.
Key takeaways
- Orion Oyj passes 9 of the 10 criteria in my screener, with a 26.5% net margin and 12.1% average annual sales growth over 5 years.
- The stock trades at roughly 45 times its free cash flow, one of the highest valuations I track outside the tech giants.
- The weak spot: the ratio of profit converting into real cash comes in at just 0.44, a figure worth watching.
- The first Nordic pharmaceutical company I cover, distinct from Belgian (UCB) or Swedish medtech (Getinge) names already analyzed.
What Orion does
Orion Oyj is a Finnish pharmaceutical company that develops and markets treatments in two main areas: central nervous system diseases (notably Parkinson's disease) and veterinary medicine. This dual focus, rare for a company this size, gives it a diversification few peers of comparable scale have.
Solid growth and profitability
Orion shows a 26.5% net margin and 12.1% average annual sales growth over five years, solid levels for a mid-sized pharmaceutical company. Free cash flow per share even grows 35.5% a year over the same period, a fast pace reflecting continuous operational efficiency improvement.
The weak spot: converting profit into cash
One figure deserves close attention: the ratio of accounting profit converting into real cash comes in at just 0.44, well below 1. That means a significant portion of Orion's reported profit doesn't immediately translate into available cash, which could reflect ongoing investment (R&D, production capacity) or longer collection delays in certain markets. It's a point worth digging into before drawing any conclusion about the quality of reported earnings.
A price that leaves no room for error
At a P/FCF of roughly 44.8, Orion trades at a very high level for a mid-sized pharmaceutical company, closer to multiples typically found in fast-growing tech. That price assumes flawless execution over the coming years: any growth slowdown or disappointment on a key treatment could weigh heavily on the stock.
The pharmaceutical moat
A pharmaceutical company's moat rests on the patents that temporarily protect its molecules from generic competition, plus the trust built with prescribing physicians over the years. Orion's diversification between human and veterinary health provides extra protection: a failure or patent expiry in one area doesn't directly hit the other.
Risks to know
The main risk remains patent expiry on its flagship treatments, which would open the door to generic competition and drive down prices and margins on those products. Pharmaceutical development also carries an inherent clinical failure risk for any new treatment in the pipeline, a factor financial analysis alone can't eliminate.
What I take away from this
Orion Oyj is a solid, diversified pharmaceutical company, but its current price assumes near-flawless execution to be justified. The below-1 profit-to-cash conversion ratio is a point I'd watch before going further. Quality is real, but it never excuses skipping the check on whether the price paid leaves enough room for error.
FAQ
What does Orion Oyj do?
It's a Finnish pharmaceutical company specialized in central nervous system treatments (including Parkinson's disease) and veterinary medicine.
Is Orion Oyj expensive on the stock market?
Yes, it trades at roughly 45 times its free cash flow, a high level for a mid-sized pharmaceutical company.
Why is Orion's profit conversion ratio so low?
It comes in at 0.44, meaning a significant portion of reported profit doesn't immediately translate into available cash, possibly tied to ongoing investment or collection delays.
What is the main risk with Orion?
Patent expiry on its flagship treatments, which would open the door to generic competition, plus the inherent clinical failure risk of pharmaceutical development.
Is Orion Oyj comparable to other companies on this site?
It's the first Nordic pharmaceutical company covered, distinct from UCB (Belgian pharma) or Getinge (Swedish medtech, not pharma).
ORNBV.HE: see the full analysis on Lubin Investment
About the author
Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).